Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Usach, Iris ^a   Melis, Virginia ^a   Peris, José Esteban ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Delavirdine; Efavirenz; Etravirine; Human immunodeficiency virus; Nevirapine; Next generation non nucleoside reverse transcriptase inhibitors; Non nucleoside reverse transcriptase inhibitors; Rilpivirine

Indexed keywords

ANTIVIRUS AGENT; BILR 355BS; CALANOLIDE A; DELAVIRDINE; DORAVIRINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSDEVIRINE; LERSIVIRINE; MILR 355BS; MK 496; MK 4965; MK 618; MK 6186; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RDEA 806; RILPIVIRINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION;

DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS; NEVIRAPINE; NEXT-GENERATION NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; RILPIVIRINE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG APPROVAL; DRUG DISCOVERY; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; TREATMENT OUTCOME;

EID: 84891550941     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18567     Document Type: Review

References (125)

1. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. 2013 [cited 2013 May 24]. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf
2. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158-63.
3. Hill A, McBride A, Sawyer AW, Clumeck N, Gupta RK. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy - implications for sustained efficacy of ART in resource-limited settings. J Infect Dis. 2013;207(Suppl 2):S78-84.
4. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1-25.
5. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol. 2002;83(Pt 6):1253-65.
6. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265:1587-90.
7. Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C, et al. Geographical distribution of HIV-1 group O viruses in Africa. AIDS. 1997;11(4):493-8.
8. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res. 2010;85(1):176-89.
9. Podzamczer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Expert Opin Pharmacother. 2001;2(12):2065-78.
10. Best BM, Goicoechea M. Efavirenz - still first-line king? Expert Opin Drug Metab Toxicol. 2008;4(7):965-72.
11. Baba M, De Clercq E, Tanaka H, Ubasawa M, Takashima H, Sekiya K, et al. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol Pharmacol. 1991;39(6):805-10.
12. Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, et al. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob Agents Chemother. 1994;38(12):2863-70.
13. Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos. 1999;20(6):285-91.
14. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999;27(8):895-901.
15. Food and Drug Administration. Viramune® XR™ (nevirapine) extended-release tablets prescribing information [Internet]. 2011 [cited 2012 Sep 20]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/201152s000lbl.pdf
16. Food and Drug Administration. Viramune® (nevirapine) prescribing information [Internet]. 2005 [cited 2012 Sep 20]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/20636s025,20933s014lbl. pdf.
17. Bristol-Myers Squibb Company. Sustiva® prescribing information [Internet]. 2009 [cited 2012 Jul 30]. Available from: http://dailymed.nlm.nih. gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10348#section-4.1.
18. Ribera E, Tuset M, Martin M, del Cacho E. Characteristics of antiretroviral drugs. Enferm Infecc Microbiol Clin. 2011;29(5):362-91.
19. AusPAR Therapeutic Goods Administration. Endurant Rilpivirineic Janssen-Cilag Pty Ltd PM-2010-03030-3-2 [Internet]. 2012 [cited 2012 Sep 2]. Available from: http://www.tga.gov.au/pdf/auspar/auspar-rilpivirine-120327.pdf
20. Gutierrez-Valencia A, Martin-Pena R, Torres-Cornejo A, Ruiz-Valderas R, Castillo-Ferrando JR, Lopez-Cortes LF. Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. J Antimicrob Chemother. 2012;67(3):681-4.
21. Scott LJ, Perry CM. Delavirdine: a review of its use in HIV infection. Drugs. 2000;60(6):1411-44.
22. Raritan N. Intelence (etravirine) tablets prescribing information [Internet]. 2010 [cited 2012 Sep 12]. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/022187s003lbl.pdf
23. Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis. 2009;48(8):1123-8.
24. O'Neil M. The Merck index-an encyclopedia of chemicals, drugs, and biologicals. 13th ed. Whitehouse Station, NJ: Merck; 2001.
25. Hawi A, Bell G. Preformulation studies of nevirapine, a reverse transcriptase inhibitor. Pharm Res. 1994;11:S236.
26. Arali B. Preparation, characterization and in vitro evaluation of nevirapine-β cyclodextrin solid complexes. Bangalore, Karnataka: Rajiv Gandhi University of Health Sciences; 2010.
27. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14(8):F77-82.
28. Hardman JG, Limbird LE, Molinoff PB, Gilman AG. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.
29. La Porte C, Burger D, Gyssens I, Sprenger H, Koopmans P, editors. Gender differences in nevirapine pharmacokinetics, fact or fiction. Fourth International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27-29; Cannes, France. Abstract 10.
30. Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, et al. Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003;17(16):2399-400.
31. Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13(5):675-85.
32. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999;27(12):1488-95.
33. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47(2):266-85.
34. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68(3):1660-6.
35. Medrano J, Barreiro P, Tuma P, Vispo E, Labarga P, Blanco F, et al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev. 2008;10(2):110-5.
36. Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, et al. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS. 2010;24(1):109-14.
37. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32(1):124-9.
38. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. AIDS. 2000;14(Suppl 4):S12.
39. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007;4(2):106-19.
40. Cheng CL, Smith DE, Carver PL, Cox SR,Watkins PB, Blake DS, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther. 1997;61(5):531-43.
41. Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1997;41(1):169-74.
42. Radi M, Angeli L, Franchi L, Contemori L, Maga G, Samuele A, et al. Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies. Bioorg Med Chem Lett. 2008;18(21):5777-80.
43. Delavirdine (Rescriptor®) prescribing information. Physicians' desk reference. 59th ed. Montvale, NJ: Medical Economics Company; 2005. p. 2529-634.
44. Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, et al. Effect of food on the steady-state pharmacokinetics of delavirdine in patients with HIV infection. Clin Drug Invest. 2003;23(4):255-61.
45. Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA, Ackland MJ. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos. 1998;26(7):631-9.
46. Vazquez E. Delavirdine levels in women. Posit Aware. 1997;8(4):14.
47. Smith PF, Dicenzo R, Forrest A, Shelton M, Friedland G, Para M, et al. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clin Pharmacokinet. 2005;44(1):99-109.
48. Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47(5):1694-9.
49. von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001;41(1):85-91.
50. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998;38(3):153-79.
51. Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000;44(3):794-7.
52. Maurin MB, Rowe SM, Blom K, Pierce ME. Kinetics and mechanism of hydrolysis of efavirenz. Pharm Res. 2002;19(4):517-21.
53. Gao JZ, Hussain MA, Motheram R, Gray DA, Benedek IH, Fiske WD, et al. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J Pharm Sci. 2007;96(11):2970-7.
54. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85-96.
55. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol. 2010;6(1):95-103.
56. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61(2):148-54.
57. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther. 2002;40(11):507-19.
58. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287-300.
59. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44(9):2475-84.
60. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-61.
61. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States [Internet]. 2009 [cited 2012 Jul 8]. Available from: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
62. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71-5.
63. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection - HRSA. Request for comments. Fed Regist. 1997;62(189):51115-6.
64. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-18.
65. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003-9.
66. Thurmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther. 1998;36(11):586-90.
67. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS. 2002;16(11):1566-8.
68. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol. 2005;88(2):209-31.
69. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther. 2009;31(4):692-704.
70. de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010;85(1):75-90.
71. Abobo CV, Wu L, John J, Joseph MK, Bates TR, Liang D. LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(30):3181-6.
72. Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561-74.
73. Scholler-Gyure M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy. 2008;28(10):1215-22.
74. Food and Drug Administration. INTELENCE® (etravirine) prescribing information [Internet]. 2011 [cited 2012 Oct 5]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022187s008lbl.pdf
75. Martinez E, Nelson M. Simplification of antiretroviral therapy with etravirine. AIDS Rev. 2010;12(1):52-9.
76. Raoof A, Mannens G, Mamidi R, Zgoda-Pols J, Hendrickx J, Willems B, et al. editors. In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers. 7th Annual Meeting of the American Association of Pharmaceutical Scientists; October 29-November 2; San Antonio, TX; 2006.
77. Kakuda T, Sekar V, Vis P, Coate B, Ryan R, Anderson D, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat. 2012;2012:186987.
78. Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, et al. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob Agents Chemother. 2009;53(11):4667-72.
79. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47(10):2550-60.
80. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, et al. editors. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. 17th International HIV Drug Resistance Workshop; 2008 Jun 10-14; Sitges, Spain. Abstract 24.
81. Eraikhuemen N, Thornton AM, Branch E, Huynh ST, Farley C. Combating non-nucleoside reverse transcriptase inhibitor resistance with a focus on etravirine (Intelence) for HIV-1 infection. P T. 2008;33(8):445-91.
82. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29-38.
83. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39-48.
84. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62(5):879-88.
85. Hodder S, Jayaweera D, Mrus J, Ryan R, Witek J, Grace Study Group. Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. AIDS Res Hum Retroviruses. 2012;28(6):544-51.
86. Janssen PAJ, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1 E)-2-cyanoethenyl]-2, 6-dimethylphenyl] amino]-2-pyrimidinyl] amino] benzonitrile (R278474, rilpivirine). J Med Chem. 2005;48(6):1901-9.
87. Mathias A, Menning M, Wiser L, Wei X, Dave A, Chuck S, et al. Bioequivalence of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate single tablet regimen. J Bioequiv Availab. 2012;4(7):100-5.
88. Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013;68(2):250-6.
89. Crauwels H, Van Heeswijk R, Bollen A, Stevens M, Buelens A, Boven K, et al. editors. The effect of different types of food on the bioavailability of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008 Apr 7-9; New Orleans, LA. Abstract P32.
90. Van Heeswijk R, Hoetelmans R, Kestens D, Stevens M, Peeters M, Boven K, et al. editors. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20-22; Lisbon. Abstract 45.
91. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
92. Tibotec Pharmaceuticals. Edurant (rilpivirine) tablets: US prescribing information [Internet]. 2011 [cited 2012 Sep 26]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202022s000lbl.pdf
93. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718-27.
94. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55-65.
95. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60(1):33-42.
96. Mascolini M, editor. Differences between women and men on rilpivirine vs efavirenz for 96 weeks. 2nd International Workshop on HIV & Women.; 2012 Jan 9-10; Bethesda, Maryland.
97. Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper D, et al. editors. Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study A5271015). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17-20; Rome, Italy. Abstract TUAB0101.
98. Zala C, Clair MS, Dudas K, Kim J, Lou Y, White S, et al. Safety and Efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects. Antimicrob Agents Chemother. 2012;56(5):2570-5.
99. Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother. 2010;54(8):3170-8.
100. Huang F, Drda K, MacGregor TR, Scherer J, Rowland L, Nguyen T, et al. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir. Antimicrob Agents Chemother. 2009;53(1):95-103.
101. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, et al. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother. 2001;45(5):1379-86.
102. Krausslich HG, Bartenschlager R. Antiviral strategies. Preface. Handb Exp Pharmacol. 2009;(189):v-vi.
103. Clinicaltrials.gov. A study of MK-1439 in human immunodeficiency virus type 1 (HIV-1)-infected participants (MK-1439-005) [Internet]. 2012 [cited 2012 Sep 12]. Available from: http://clinicaltrials.gov/ct2/show/NCT01466985?term= mk1439&rank=2.
104. Clinicaltrials.gov. MK6186 in HIV-1 infected patients (MK-6186-007 AM2) [Internet]. 2011 [cited 2012 Sep 20]. Available from: http://clinicaltrials.gov/ ct2/show/NCT01152255?term=MK-6186&rank=1
105. AIDS InfoNet. Non-nucleoside reverse transcriptase inhibitors in development. Fact sheet number 430 [Internet]. 2011 [cited 2012 Oct 2012]. Available from: http://www.aidsinfonet.org/uploaded/factsheets/59-eng-430.pdf
106. Vourvahis M, Banerjee S, LaBadie R, Gore D, Mayer H. Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine. Antimicrob Agents Chemother. 2010;54(5):2209-11.
107. Mori J, Corbau R, Lewis D, Ellery S, Mayer H, Perros M, et al. editors. In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston, MA. Abstract F-134.
108. Vourvahis M, Gleave M, Nedderman ANR, Hyland R, Gardner I, Howard MR, et al. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl) (3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010;38(5):789-800.
109. Fätkenheuer G, Staszewski S, Plettenburg A, Hackman F, Layton G, McFadyen L, et al. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS. 2009;23(16):2115.
110. Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr. 2013;62(2):171-9.
111. ViiV Healthcare. Update Status of Lersivirine Development Program [Internet]. 5 February 2013 [cited 2013 Jun 4]. Available from: http://www.viivhealthcare.com/r-and-d/our-pipeline
112. Ford S, Kim J, Yu L, Gould E, White S, Piscitelli S, et al. editors. Inhibition potential for GSK2248761, a next-generation NNRTI, on HMG-CoA reductase inhibitors simvastatin, atorvastatin and rosuvastatin. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 2011 Apr 13-15; Miami, FL.
113. Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, et al. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol. 2012;74(2):336-45.
114. AIDSMEDS. FDA puts a hold on development of ViiV HIV drug [Internet]. 2011 [cited 2013 Jun 3]. Available from: http://www.aidsmeds.com/articles/hiv- gsk761-idenix-1667-19885.shtml
115. Xu W, Groschel B, Straney R, Zhang Z, Bellows D, Hamatake R, et al. editors. Resistance to RDEA806 requires multiple mutations which have limited cross-resistance to other NNRTIs. 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008); 2008 Oct 25-28; Washington, DC. Abstract H-1222.
116. Boone LR. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Invest Drugs. 2006;7(2):128-35.
117. Huang F, Scholl P, Huang DB, MacGregor TR, Vinisko R, Castles MA, et al. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(7):1061-70.
118. Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, et al. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012;37(1):81-8.
119. Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, et al. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study. Basic Clin Pharmacol Toxicol. 2011;108(3):163-70.
120. Xu ZQ, Flavin MT, Jenta TR. Calanolides, the naturally occurring anti-HIV agents. Curr Opin Drug Discov Devel. 2000;3(2):155-66.
121. Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, et al. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. J Med Chem. 2008;51(23):7449-58.
122. Su DS, Lim JJ, Tinney E, Wan BL, Young MB, Anderson KD, et al. Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses. J Med Chem. 2009;52(22):7163-9.
123. Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, et al. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2009;53(6):2424-31.
124. Lu M, Felock PJ, Munshi V, Hrin RC,Wang YJ, Yan Y, et al. Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012;56(6):3324-35.
125. Lai M, Feng M, Lu M, Asante-Appiah E, Tawa P, Witmer M, et al. editors. Antiviral activity and in vitro mutation development pathways of MK-1439: a novel non-nucleoside reverse transcriptase inhibitor. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012); 2012 Sep 9-12; San Francisco, CA. Abstract H-551.